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A B S T R A C T
Four disease-specific induced pluripotent stem cell (iPSC) lines were respectively derived from peripheral blood mononuclear cells of two affected individuals in a
family affected by familial neurohypophyseal diabetes insipidus carrying the c.314G>C mutation. The expression of pluripotency markers (NANOG, OCT4, and
SOX2), maintenance of a normal karyotype, absence of episomal vectors used for iPSC generation, and presence of the original pathogenic mutation were confirmed
for each iPSC line. The ability to differentiate into three germ layers was confirmed by a teratoma formation assay. These iPSC lines can help in disease recapitulation
in vitro using organoids and elucidation of disease mechanisms.
Resource Table
Unique stem cell lines
identifier
FHUi003-A
FHUi003-B
FHUi004-A
FHUi004-B
Alternative names of st-
em cell lines
FNDI-iPS-A1b, A1b2as1 (FHUi003-A)
FNDI-iPS-A11b, A11b (FHUi003-B)
FNDI-iPS-B3a, B3a (FHUi004-A)
FNDI-iPS-B7a, B7as1 (FHUi004-B)
Institution Fujita Health University School of Medicine
Contact information of
distributor
Akifumi Matsuyama, akifumi-matsuyama@umin.ac.jp
Type of cell lines iPSC
Origin Human
Cell Source Peripheral blood mononuclear cells (PBMCs)
Clonality Clonal
Method of reprogram-
ming
Transgene free (Episomal vectors)
Multiline rationale Two lines from each of two patients (a male and a female)
of the same family, harboring the same disease and genetic
mutation
Gene modification YES
Type of modification Hereditary
Associated disease Familial neurohypophyseal diabetes insipidus (FNDI)
Resource Table (continued)
Gene/locus AVP/20p13
Method of modification N/A
Name of transgene or r-
esistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock da-
te
December 2019
Cell line repository/ba-
nk
https://hpscreg.eu/cell-line/FHUi003-A
https://hpscreg.eu/cell-line/FHUi003-B
https://hpscreg.eu/cell-line/FHUi004-A
https://hpscreg.eu/cell-line/FHUi004-B
Ethical approval Ethics Committee of Fujita Health University School of
Medicine (approval number HG19-062).
Ethical Committee of Nagoya University Hospital (ap-
proval number 2018-006-4).
Ethical Committee of Mitoyo General Hospital (approval
number 18CR01-067).
All animal experiments were approved by the Animal Care
and Use Committee of KATAGIRI VMD OFFICE (approval
number FHU19-1).
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1. Resource utility
The lack of good in vitro models of familial neurohypophyseal dia-
betes insipidus (FNDI) has made pathological analysis difficult. The
generated FNDI-iPSCs can be useful for disease recapitulation in vitro
using the hypothalamic-pituitary unit of organoids (Kasai et al., 2020;
Suga, 2016), along with elucidation of the pathology and drug dis-
covery Table 1.
2. Resource details
FNDI is a progressive form of diabetes insipidus caused by mutation
in the AVP gene, which encodes a preproprotein including the anti-
diuretic hormone arginine vasopressin (AVP), AVP carrier protein
neurophysin 2, and copeptin. The mutation leads to deficient AVP se-
cretion from the pituitary gland, resulting in excessive and thin urine
production accompanied by a polyuric symptom due to impaired water
reabsorption in the kidneys (Arima and Oiso, 2010; Hagiwara et al.,
2019). We generated disease-specific iPSCs from peripheral blood
mononuclear cells (PBMCs) of two donor patients of an FNDI family,
both of whom carry a heterozygous mutation (c.314G>C) in the
neurophysin 2-coding region of AVP. We here report two iPSC lines
derived from each of the two patients for a total of four cell lines.
Characterization of the iPSC lines is summarized in Table 2. Each
generated iPSC colony was picked and expanded. Each iPSC line shows
the typical iPSC morphology with a high nucleus to cytoplasm ratio
(Fig. 1A), and expression of pluripotent markers NANOG, OCT4, and
SOX2 was confirmed by immunocytochemical analysis (Fig. 1B). Posi-
tive cells for the markers in at least three independent areas were de-
tected for each iPSC line with an average positive ratio of> 95%,>
92%, and>95% for NANOG, OCT4, and SOX2, respectively (Fig. 1D;
Table 2). The ability of each iPSC line to differentiate into the three
germ layers was confirmed by an in vivo teratoma formation assay;
histological analysis of the developed teratoma revealed formation of
the neural tissue (ectoderm), cartilage and muscle (mesoderm), and
gut-like columnar epithelium (endoderm, Fig. 1C). Differentiation into
pigment cells (ectoderm) and the adipose tissue (mesoderm) was also
found in FNDI-A1b (FHUi003-A) and FNDI-A11b (FHUi003-B)
(Fig. 1C). After more than a dozen passage cultures, none of the residual
episomal vectors used for generating the iPSCs was detected by poly-
merase chain reaction (PCR) analysis targeting the DNA sequence of
OriP and EBNA1 in the vector (Fig. 1E). The original heterozygous
mutation causing the disease was confirmed in the iPSCs derived from
both patients by sequencing (Fig. 1F). G-banding analysis showed a
normal karyotype of each iPSC line as 46XY (FNDI-A1b and A11b) or
46XX (FNDI-B3a and B7a; Supplementary Fig. 1A). No sign of Myco-
plasma infection was detected by the MycoAlert™ assay (Supplementary
Fig. 1B). The identity of each iPSC line was confirmed by STR analysis
(submitted in archive with journal) with an evaluation value of 1.
3. Materials and methods
3.1. Generation iPSCs
PBMCs were separated from whole blood of the patients using
density-gradient centrifugation with Lympho Spin Medium
(pluriSelect) and cultured for 5 days in PBMC medium (StemFit®
AK02N medium (Ajinomoto) without C solution, supplemented with
50 ng/mL of IL-6, 50 ng/mL of SCF, 10 ng/mL of TPO, 20 ng/mL of Flt-
3L, 20 ng/mL of IL-3, and 10 ng/mL of G-CSF). On day 5, to generate
iPSCs from PBMCs, episomal vectors of transgenes for reprogramming
(Epi5™ Episomal iPSC Reprogramming Kit, Thermo Fisher Scientific)
were delivered into the cultured PBMCs by electroporation using 4D-
Nucleofector™ System (Lonza) with the P3 Primary Cell 4D-
Nucleofector™ X kit and the pre-installed program EO-117 according to
the manufacturer’s instructions. The Cells were plated with PBMC
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
FNDI-iPS-A1b, A1b2as1 (FHUi003-A) FNDI_A1b Male 71 Japanese c.314G>C, heterozygous Familial neurohypophyseal diabetes insipidus
FNDI-iPS-A11b, A11b (FHUi003-B) FNDI_A11b Male 71 Japanese c.314G>C, heterozygous Familial neurohypophyseal diabetes insipidus
FNDI-iPS-B3a, B3a (FHUi004-A) FNDI_B3a Female 45 Japanese c.314G>C, heterozygous Familial neurohypophyseal diabetes insipidus
FNDI-iPS-B7a, B7as1 (FHUi004-B) FNDI_B7a Female 45 Japanese c.314G>C, heterozygous Familial neurohypophyseal diabetes insipidus
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Qualitative analysis (Immunocytochemistry) Positive staining for NANOG, OCT4, and SOX2 Fig. 1 panel B
Quantitative analysis (Immunocytochemistry
counting)
NANOG: >95%
OCT4: > 92%
SOX2: > 95%
Fig. 1 panel D
Genotype Karyotype (G-banding) and resolution FNDI-A1b, A11b: 46XY
FNDI-B3a, B7a: 46XX
Resolution 300–500
Supplementary Fig. 1 panel A
Identity Microsatellite PCR (mPCR) OR
STR analysis
Not performed N/A
16 STR loci tested;
16/16 matched
Submitted in archive with
journal
Mutation analysis (IF APPLICABLE) Sequencing Heterozygous mutation,
NM_000490:c.314G>C
Fig. 1 panel F
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence. Negative Supplementary Fig. 1 panel B
Differentiation potential Teratoma formation Ectoderm: neural tissue, pigment cells
Mesoderm: cartilage, muscle, adipose tissue
Endoderm: Gut-like columnar epithelium
Fig. 1 panel C
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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Fig. 1. Characterization of generated FNDI-iPSC lines.
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medium onto a multi-well plate coated with iMatrix-511 (Nippi) and
the half volume of complete StemFit® medium were added on day 3, 5,
and 7. After day 9, medium change with fresh StemFit® medium was
performed every 2–3 days until the iPSCs colonies grew enough for
picking. Obtained iPSC colonies were individually picked and trans-
ferred onto new multi-well plates coated with iMatrix-511, followed by
culture in StemFit® for further expansion. For subculture, the cultured
iPSCs were dissociated using Accutase (Innovative Cell Technologies)
and plated onto an iMatrix-511-coated plate once a week. During dis-
sociation and plating, 10 µM of the ROCK-inhibitor Y-27632 (Cayman
Chemical) was added to the media and was removed after culture day 1.
Cells were maintained at 37 °C in a humidified 5% CO2 incubator. To
confirm the absence of the reprograming vectors in the iPSCs, total DNA
isolated from the established iPSCs at passage (P14–P17) using
QIAamp® DNA mini kit (QIAGEN) was subjected to PCR analysis using
the specific primer pairs listed in Table 3. DNA from cells at P1 carrying
the episomal vector was used as a positive control.
3.2. Immunocytochemistry
The expression of pluripotent markers was examined by fluorescent
immunocytochemistry. iPSCs were fixed with 4% paraformaldehyde for
10 min. The blocking reaction and dilution of antibodies (Table 3) were
performed using 5% normal donkey serum (Jackson Immunoresearch)
in phosphate-buffered saline with 0.01% Triton-X. The fixed cells were
incubated with the primary antibody overnight at 4 °C, followed by
reaction with the secondary antibodies for 1 h at room temperature.
The fluorescent signal was visualized using a BX-51 fluorescent mi-
croscope and DP71 digital camera (Olympus).
3.3. Teratoma formation assay
A teratoma formation assay was performed to assess the differ-
entiation ability of the iPSCs. A total of 5 × 105 iPSCs (P21–P24) were
suspended in Matrigel (Corning) diluted in StemFit® AK02N at a 1:1
ratio and injected into the testes of 7-week-old NOD.CB17-Prkdcscid/Jcl
mice (CLEA Japan). Fourteen weeks after injection, the animals were
sacrificed and the developed teratoma was excised. Paraffin-embedded
sections prepared from the excised tissue were stained with hematox-
ylin and eosin for histological analysis. All animal experiments were
conducted by KATAGIRI-OFFICE.
3.4. Direct sequencing
Direct sequencing was performed to detect the pathogenic mutation
in the established iPSCs. The target region of the isolated genomic DNA
was amplified by PCR using Blend Taq® Plus (TOYOBO) and the primer
pair listed in Table 3. PCR products purified using LaboPass™ PCR
(COSMO GENETECH) were subjected to cycle sequencing by Eurofin
Genomics using the primer shown in Table 3.
3.5. Karyotype analysis
The karyotype of 20 cells (P25–P28) in metaphase was examined for
each iPSC line by G-banding at Nihon Gene Research Laboratories.
3.6. STR analysis
The identity of each established iPSC line was confirmed by STR
analysis using the PowerPlex® 16 System (Promega) at BEX Co., Ltd.
3.7. Mycoplasma test
Mycoplasma contamination was tested using MycoAlert™
Mycoplasma Detection Kit (Lonza) according to the manufacturer’s
instructions. The test was performed at the same time as the test for
MEN1-iPSC lines, which previously we reported (Yoshida et al., 2020),
and the same negative/positive control value was shown
(Supplementary Fig. 1B).
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Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-OCT4 1:500 Abcam Cat# ab19857, RRID: AB_445175
Rabbit anti-SOX2 1:1000 Wako Cat# 012-27541, RRID: N/A
Mouse anti-NANOG 1:1000 Thermo Fisher Scientific Cat# MA1-017, RRID: AB_2536677
Secondary antibodies Alexa Fluor® 488 AffiniPure Donkey
Anti-Rabbit IgG (H + L)
1:100 Jackson ImmunoResearch Labs Cat# 711-545-152, RRID:AB_2313584
Cy3-AffiniPure Donkey Anti-Mouse
IgG (H + L)
1:100 Jackson ImmunoResearch Labs Cat# 715-165-151, RRID:AB_2315777
Primers
Target Forward/Reverse primer (5′-3′)
Episomal Plasmids (PCR) OriP TTCCACGAGGGTAGTGAACC/TCGGGGGTGTTAGAGACAAC
EBNA1 TGGACGTGGAGAAAAGAGGC/CAAAGCTGCACACAGTCACC
Internal Control GAPDH GTGGACCTGACCTGCCGTCT/GGAGGAGTGGGTGTCGCTGT
Targeted mutation analysis/
sequencing
AVP TGTAAAACGACGGCCAGTTCCCCTCCAACCCCTCGACTCCCG/
CAGGAAACAGCTATGACTCGGGCTCGGTCACGCAGCTCTCTGC
M13_-20 CGACGTTGTAAAACGACGGCCAGT
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2020.101960.
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